glp-1 meds corona Safety Check GLP-1 Medications for Weight Loss:

Key Mergers and Acquisitions January 2026: Eli Lilly and Company acquired a biotech firm developing next-generation dual GLP-1/GIP agonists to expand its obesity and diabetes portfolio beyond Mounjaro and Zepbound

In a recent phase III clinical trial for overweight patients without diabetes, using Semalutide 2.4mg once a week, after 68 weeks of treatment, the body weight decreased by 14.9%, compared with 2.4% in the control group

Its important to note that while these findings show a statistical association, they do not confirm a direct cause

Absorption rates can vary slightly between sites

Always consult your physician before starting any new supplement, especially if pregnant, nursing, on medication, or under 18